Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is reporting positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. According to the announcement, SPU-21 is effective in controlling arthritis progression and exhibits positive data in arthritis suppression. The company noted that it is following a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (“RA”). The study is designed to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug compared to the drug alone. SILO is working with the University of Maryland, Baltimore to develop the SPU-21 liposomal joint homing peptides. “We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression,” said Silo Pharma CEO Eric Weisblum in the press release. “The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route. Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”

To view the full press release, visit https://ibn.fm/X9YF3

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork